/
© 2026 RiffOn. All rights reserved.

Get your free personalized podcast brief

We scan new podcasts and send you the top 5 insights daily.

  1. OncLive® On Air
  2. S19 Ep11: Weigh Benefit Against Burden: Defining Lurbinectedin’s Role in a Shifting Small Cell Lung Cancer Landscape
S19 Ep11: Weigh Benefit Against Burden: Defining Lurbinectedin’s Role in a Shifting Small Cell Lung Cancer Landscape

S19 Ep11: Weigh Benefit Against Burden: Defining Lurbinectedin’s Role in a Shifting Small Cell Lung Cancer Landscape

OncLive® On Air · Oct 19, 2026

Lurbinectedin plus atezolizumab maintenance improves PFS/OS in ES-SCLC, but toxicity and emerging tarlatamab data will define its role.

G-CSF allowance explains lower neutropenia in IMforte

Dr Sands says IMforte’s lower neutropenia rate versus the prior second-line lurbinectedin trial likely reflects allowed primary G-CSF prophylaxis, not an intrinsically safer regimen. The combination still raised anemia, neutropenia, and thrombocytopenia when added to atezolizumab maintenance, so toxicity remains a real tradeoff for patients.

S19 Ep11: Weigh Benefit Against Burden: Defining Lurbinectedin’s Role in a Shifting Small Cell Lung Cancer Landscape thumbnail

S19 Ep11: Weigh Benefit Against Burden: Defining Lurbinectedin’s Role in a Shifting Small Cell Lung Cancer Landscape

OncLive® On Air·a month ago

Modern SCLC control arms beat lurbinectedin's approval benchmark

Dr Sands says Lagoon’s second-line control arm had median overall survival above 10 months, which was surprising. Lurbinectedin’s initial FDA approval rested on a single-arm study with 9.3-month median survival, so today’s second-line comparator sets a higher bar than the old benchmark for relapsed disease.

S19 Ep11: Weigh Benefit Against Burden: Defining Lurbinectedin’s Role in a Shifting Small Cell Lung Cancer Landscape thumbnail

S19 Ep11: Weigh Benefit Against Burden: Defining Lurbinectedin’s Role in a Shifting Small Cell Lung Cancer Landscape

OncLive® On Air·a month ago

Swapping PD-L1 inhibitors won't settle lurbinectedin's maintenance role

Dr Sands says no one expects durvalumab to work differently from atezolizumab when paired with lurbinectedin. Even a positive durvalumab trial that merely matches atezolizumab data would still not answer the larger question of whether lurbinectedin belongs in first-line maintenance for extensive-stage SCLC at all.

S19 Ep11: Weigh Benefit Against Burden: Defining Lurbinectedin’s Role in a Shifting Small Cell Lung Cancer Landscape thumbnail

S19 Ep11: Weigh Benefit Against Burden: Defining Lurbinectedin’s Role in a Shifting Small Cell Lung Cancer Landscape

OncLive® On Air·a month ago

Delphi 305 is the real threat to lurbinectedin maintenance

Dr Sen says the biggest challenge to lurbinectedin maintenance is Delphi 305, which tests terlatumab plus durvalumab against durvalumab alone after induction chemoimmunotherapy. Its phase 3 results could reshape first-line maintenance before the durvalumab-lurbinectedin question matters, so it is the single key readout to watch.

S19 Ep11: Weigh Benefit Against Burden: Defining Lurbinectedin’s Role in a Shifting Small Cell Lung Cancer Landscape thumbnail

S19 Ep11: Weigh Benefit Against Burden: Defining Lurbinectedin’s Role in a Shifting Small Cell Lung Cancer Landscape

OncLive® On Air·a month ago

SCLC scan waxing makes ADC ILD attribution difficult

Dr Sands notes small cell lung cancer scans often show waxing and waning inflammatory findings. That makes a grade 1 radiographic ILD hard to attribute to a B7H3 antibody-drug conjugate; if drug-related ILD is suspected, he says hold the drug, treat aggressively with steroids, and monitor for improvement.

S19 Ep11: Weigh Benefit Against Burden: Defining Lurbinectedin’s Role in a Shifting Small Cell Lung Cancer Landscape thumbnail

S19 Ep11: Weigh Benefit Against Burden: Defining Lurbinectedin’s Role in a Shifting Small Cell Lung Cancer Landscape

OncLive® On Air·a month ago

Mature IMforte curves converge, questioning durability

Dr Sands says that as IMforte data matured, the tails of the progression-free and overall survival curves came together. That convergence suggests the early hazard ratios may overstate how durable the lurbinectedin maintenance benefit is over time for extensive-stage SCLC in the first-line maintenance setting.

S19 Ep11: Weigh Benefit Against Burden: Defining Lurbinectedin’s Role in a Shifting Small Cell Lung Cancer Landscape thumbnail

S19 Ep11: Weigh Benefit Against Burden: Defining Lurbinectedin’s Role in a Shifting Small Cell Lung Cancer Landscape

OncLive® On Air·a month ago